SARCULATOR vs HemeOncBuddy

This app is meant to be used only by physicians and it is not meant to make clinical decisions (the clinical usefulness of the two models has not been tested) but to be used as an informative tool to improve the predictive capability of a physician. Two kinds of predictions are possible: - RPS: 5-year overall survival (OS) and 5-year disease-free survival (DFS) in primary resected retroperitoneal sarcoma (RPS) patients. . - ESTS: 5- and 10-year overall survival (OS) and cumulative incidence of distant metastasis (CCI of DM) in primary resected extremity STS patients.

HemeOncBuddy is a free study hub built for hematology and oncology fellows and trainees - everything you need to keep up with the literature and prep for boards, in one fast, searchable app. WHAT'S INSIDE - 1,500+ pivotal clinical-trial summaries, each in the same structure (background, inclusion criteria, arms, primary/secondary endpoints, median follow-up, key results, notable toxicities) so you can scan them quickly. - A Question Bank with board-style questions, tutor and timed modes, explanations, and progress tracking. - ~2,000 active-recall flashcards across oncology, malignant and benign heme, and pharmacology — plus visual staging decks. - 120+ concise disease-site board-prep notes. - A conference & abstract-deadline tracker so you never miss a submission window. MADE FOR STUDYING - Full dark mode and adjustable text size. - Optional free account (Sign in with Apple, Google, or email) to sync your saved trials, Qbank progress, and notes across iPhone, iPad, and Mac. - No ads. No paywall. No login required to browse. HemeOncBuddy is an educational study aid only. It is not a substitute for medical advice, clinical judgment, or current guidelines, and must not be used to diagnose or treat patients. Always verify against primary literature and current guidelines.